-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

Benzinga·11/06/2025 20:16:08
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $25 to $24.